PDF herunterladen
Nervenheilkunde 2025; 43(04): 211-221
DOI: 10.1055/a-2509-9705
Übersichtsarbeit

Das Blutungsrisiko unter Antidepressiva verstehen und einschätzen

Understanding and assessing the antidepressant drug-associated risk of bleeding
Johanna Seifert
1   Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover, Hannover, Germany
,
Gabriel Eckermann
2   Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie, Arbeitsgruppe Polypharmazie, München, Germany
,
Johannes Heck
3   Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover, Hannover, Germany
,
Stefan Bleich
1   Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover, Hannover, Germany
,
Dominik Dabbert
4   Klinik für Forensische Psychiatrie und Psychotherapie, Klinikum Bremen-Ost gGmbH, Bremen, Germany
,
Renate Grohmann
5   Psychiatrie und Psychotherapie, Klinik und Poliklinik der Ludwig-Maximilians-Universität München, München, Germany
,
Sermin Toto
1   Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover, Hannover, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Antidepressiva, insbesondere die selektiven Serotoninwiederaufnahmehemmer (SSRI), sind die meistverordnete psychopharmakologische Arzneistoffgruppe, weshalb eine genaue Kenntnis der zu erwartenden unerwünschten Arzneimittelwirkungen unabdingbar ist. Das erhöhte Risiko für Blutungsereignisse ist vor allem bei Patienten, die mit SSRI behandelt werden, gut belegt. Mit wenigen Ausnahmen können jedoch auch die anderen antidepressiven Arzneistoffgruppen Einfluss auf die Blutgerinnung nehmen und somit das Blutungsrisiko erhöhen. In der nachfolgenden Übersichtsarbeit wird das thrombozytäre Serotoninsystem vorgestellt und die Angriffspunkte der unterschiedlichen Antidepressiva erläutert. Anschließend wird die zur Verfügung stehende Literatur zu Blutungen unter den jeweiligen Antidepressivaklassen bzw. einzelnen Substanzen vorgestellt, wobei hier nach Möglichkeit jeweils Daten aus Meta-Analysen herangezogen werden. Neben dem allgemeinen Blutungsrisiko werden zudem einzelne Blutungsentitäten betrachtet, wie gastrointestinale und Hirnblutungen. Zuletzt werden die Auswirkungen von anderen blutgerinnungsfördernden Arzneistoffen (Nichtsteroidale Antirheumatika, Thrombozytenaggregationshemmer und Antikoagulanzien) in Kombination mit Antidepressiva diskutiert. Mit dem vorgestellten Wissen soll es Behandlern in Zukunft leichter fallen Entscheidungen hinsichtlich einer geeigneten antidepressiven Pharmakotherapie anhand der patientenindividuellen Risikokonstellation zu treffen.

Abstract

Antidepressants, in particular selective serotonin reuptake inhibitors (SSRIs), are the most commonly prescribed psychopharmacological drug group. Thus, a precise knowledge of the expected adverse drug reactions is indispensable. The increased risk of bleeding events is well documented, especially in patients treated with SSRIs. However, many other antidepressant drug groups have also been implicated in increasing the risk of bleeding. In the following review, the thrombocytic serotonin system and the respective targets of the different antidepressants are explained. Subsequently, the available literature on bleeding under the respective antidepressant classes or individual substances is presented, using data from metaanalyses whenever possible. In addition to the risk of bleeding in general, individual bleeding entities are also considered, such as gastrointestinal and cerebral hemorrhages. Finally, the effects of other drugs that increase the risk of bleeding (i. e., nonsteroidal anti-inflammatory drugs, platelet aggregation inhibitors and anticoagulants) in combination with antidepressant drugs are discussed. The information presented here is meant to guide practitioner’s decision making regarding an appropriate antidepressant pharmacotherapy based on the patient’s individual risk constellation.

Schlüsselwörter

Antidepressiva - Gerinnung - Blutung - Thrombozyten - Serotonin

Keywords

antidepressant drugs - hemostasis - bleeding - thrombocyte - serotonin


Publikationsverlauf

Artikel online veröffentlicht:
03. April 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Seifert J, Bleich S, Seifert R. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizithyperaktivitätssyndrom. In: Arzneiverordnungs-Report 2022. Springer; 2023: 451-495
    CrossrefSuche in Google Scholar
  • 2 Noordam R, Aarts N, Verhamme KM. et al. Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. Eur J Clin Pharmacol 2015; 71: 369-375
    CrossrefPubMedSuche in Google Scholar
  • 3 Lako IM, Taxis K, Bruggeman R. et al. The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. Eur Psychiatry 2012; 27: 240-244
    CrossrefPubMedSuche in Google Scholar
  • 4 Jelkmann W. Allgemeine Eigeschaften des Blutes. In: Brandes R, Lang F, Schmidt RF. Hrsg. Physiologie des Menschen mit Pathophysiologie. 32. Aufl. Springer; Berlin, Heidelberg: 2019: 285-305
    CrossrefSuche in Google Scholar
  • 5 Gamoh S, Hisa H, Yamamoto R. 5-hydroxytryptamine receptors as targets for drug therapies of vascular-related diseases. Biol Pharm Bull 2013; 36: 1410-1415
    CrossrefPubMedSuche in Google Scholar
  • 6 Cloutier N, Allaeys I, Marcoux G. et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proceedings of the National Academy of Sciences 2018; 115: E1550-E1559
    CrossrefPubMedSuche in Google Scholar
  • 7 Li N, Wallén NH, Ladjevardi M. et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517-523
    CrossrefPubMedSuche in Google Scholar
  • 8 Duerschmied D, Bode C. [The role of serotonin in haemostasis]. Hamostaseologie 2009; 29: 356-359
    Thieme ConnectPubMedSuche in Google Scholar
  • 9 Kawano Y, Obana M, Nagata M. et al. The antiplatelet effect of mirtazapine is mediated by co-blocking 5-HT(2 A) and α(2)-adrenergic receptors on platelets: An in vitro human plasma-based study. Eur J Pharmacol 2022; 917: 174640
    CrossrefPubMedSuche in Google Scholar
  • 10 Youdim MBH. Platelet monoamine oxidase B: Use and misuse. Experientia 1988; 44: 137-141
    CrossrefPubMedSuche in Google Scholar
  • 11 Meijer WEE, Heerdink ER, Nolen WA. et al. Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants. Arch Internal Med 2004; 164: 2367-2370
    CrossrefPubMedSuche in Google Scholar
  • 12 Castro VM, Gallagher PJ, Clements CC. et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open 2012; 2: e000544
    CrossrefPubMedSuche in Google Scholar
  • 13 Lewis JD, Strom BL, Localio AR. et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf 2008; 17: 328-335
    CrossrefPubMedSuche in Google Scholar
  • 14 Wang YP, Chen YT, Tsai CF. et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014; 171: 54-61
    CrossrefPubMedSuche in Google Scholar
  • 15 Renoux C, Vahey S, Dell’Aniello S. et al. Association of Selective Serotonin Reuptake Inhibitors With the Risk for Spontaneous Intracranial Hemorrhage. JAMA Neurol 2017; 74: 173-180
    CrossrefPubMedSuche in Google Scholar
  • 16 Wu CS, Wang SC, Cheng YC. et al. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry 2011; 168: 511-521
    CrossrefPubMedSuche in Google Scholar
  • 17 Stórustovu S, Sánchez C, Pörzgen P. et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 2004; 142: 172-180
    CrossrefPubMedSuche in Google Scholar
  • 18 Bayoumi AB, Ikizgul O, Karaali CN. et al. Antidepressants in Spine Surgery: A Systematic Review to Determine Benefits and Risks. Asian Spine J 2019; 13: 1036-1046
    CrossrefPubMedSuche in Google Scholar
  • 19 Cheng YL, Hu HY, Lin XH. et al. Use of SSRI, But Not SNRI, Increased Upper and Lower Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in Taiwan. Medicine (Baltimore) 2015; 94: e2022
    CrossrefPubMedSuche in Google Scholar
  • 20 Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG. et al. Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors. Neuropsychopharmacology 2001; 25: 871-880
    CrossrefPubMedSuche in Google Scholar
  • 21 Yuet WC, Derasari D, Sivoravong J. et al. Selective Serotonin Reuptake Inhibitor Use and Risk of Gastrointestinal and Intracranial Bleeding. J Am Osteopath Assoc 2019; 119: 102-111
    CrossrefPubMedSuche in Google Scholar
  • 22 Eslami Shahrbabki M, Eslami Shahrbabaki A. Sertraline-related bleeding tendency: could it be dose-dependent?. Iran J Psychiatry Behav Sci 2014; 8: 81-83
    PubMedSuche in Google Scholar
  • 23 Nelson JC. Tricyclic and tetracyclic drugs. The American Psychiatric Association Publishing Textbook of Psychopharmacology 5th ed. Arlington, VA: American Psychiatric Association Publishing; 2017: 305-334
    Suche in Google Scholar
  • 24 BindungDB. Zugriff am 09. Februar 2023 unter: https://www.bindingdb.org/rwd/bind/index.jsp
  • 25 PDSP Ki Database. Zugriff am 09. Februar 2023 unter: https://pdsp.unc.edu/databases/kidb.php
  • 26 Anglin R, Yuan Y, Moayyedi P. et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 811-819
    CrossrefPubMedSuche in Google Scholar
  • 27 Jiang HY, Chen HZ, Hu XJ. et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 42-50.e43
    CrossrefPubMedSuche in Google Scholar
  • 28 Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. Ann Pharmacother 2019; 53: 186-194
    CrossrefPubMedSuche in Google Scholar
  • 29 Laporte S, Chapelle C, Caillet P. et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res 2017; 118: 19-32
    CrossrefPubMedSuche in Google Scholar
  • 30 Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry 2004; 65: 1642-1653
    CrossrefPubMedSuche in Google Scholar
  • 31 Trajkova S, dʼErrico A, Soffietti R. et al. Use of Antidepressants and Risk of Incident Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology 2019; 53: 142-151
    CrossrefPubMedSuche in Google Scholar
  • 32 Singh I, Achuthan S, Chakrabarti A. et al. Influence of pre-operative use of serotonergic antidepressants (SADs) on the risk of bleeding in patients undergoing different surgical interventions: a meta-analysis. Pharmacoepidemiol Drug Saf 2015; 24: 237-245
    CrossrefPubMedSuche in Google Scholar
  • 33 Roose SP, Rutherford BR. Selective Serotonin Reuptake Inhibitors and Operative Bleeding Risk: A Review of the Literature. J Clin Psychopharmacol 2016; 36: 704-709
    CrossrefPubMedSuche in Google Scholar
  • 34 Zafirova Z, Vázquez-Narváez KG, Borunda D. Preoperative Management of Medications. Anesthesiol Clin 2018; 36: 663-675
    CrossrefPubMedSuche in Google Scholar
  • 35 Jiang HY, Xu LL, Li YC. et al. Antidepressant use during pregnancy and risk of postpartum hemorrhage: A systematic review and meta-analysis. J Psychiatr Res 2016; 83: 160-167
    CrossrefPubMedSuche in Google Scholar
  • 36 Marcinkowska M, Kubacka M, Zagorska A. et al. Exploring the antiplatelet activity of serotonin 5-HT(2 A) receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif- as potential therapeutic agents in the prevention of cardiovascular diseases. Biomed Pharmacother 2022; 145: 112424
    CrossrefPubMedSuche in Google Scholar
  • 37 Arnold DM, Nazi I, Warkentin TE. et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013; 27: 137-145
    CrossrefPubMedSuche in Google Scholar
  • 38 Stuhec M, Alisky J, Malesic I. Mirtazapine associated with drug-related thrombocytopenia: a case report. J Clin Psychopharmacol 2014; 34: 662-664
    CrossrefPubMedSuche in Google Scholar
  • 39 Na K-S, Jung H-Y, Cho S-J. et al. Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis. J Affect Disord 2018; 225: 221-226
    CrossrefPubMedSuche in Google Scholar
  • 40 de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319: 1106-1109
    CrossrefPubMedSuche in Google Scholar
  • 41 Coupland C, Dhiman P, Morriss R. et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Bmj 2011; 343: d4551
    CrossrefPubMedSuche in Google Scholar
  • 42 Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie. Berlin, Germany: Springer; 2021
    Suche in Google Scholar
  • 43 Vardar MK, Kovalak EE. Abnormal Uterine Bleeding Associated with Bupropion: A Case Report. Bagcilar Med Bul 2022; 7: 288-290
    CrossrefSuche in Google Scholar
  • 44 Frankhauser P, Grimmer Y, Bugert P. et al. Characterization of the neuronal dopamine transporter DAT in human blood platelets. Neurosci Lett 2006; 399: 197-201
    CrossrefPubMedSuche in Google Scholar
  • 45 Schedel A, Schloss P, Klüter H. et al. The dopamine agonism on ADP-stimulated platelets is mediated through D2-like but not D1-like dopamine receptors. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 431-439
    CrossrefPubMedSuche in Google Scholar
  • 46 Dhawan BN, Mathur GB, Rajvanshi VS. Effects of some centrally acting drugs on blood coagulation. Jpn J Pharmacol 1968; 18: 445-453
    CrossrefPubMedSuche in Google Scholar
  • 47 Juang H-T, Chen P-C, Chien K-L. Using antidepressants and the risk of stroke recurrence: report from a national representative cohort study. BMC Neurology 2015; 15: 86
    CrossrefPubMedSuche in Google Scholar
  • 48 Sheikh Rezaei S, Mittlböck M, Reichardt B. et al. SSRI co-medication with NOAC or VKA does not increase hospitalisation for bleeding: A retrospective nationwide cohort study in Austria 2010–2015. Int J Geriatr Psychiatry 2019; 34: 1194-1199
    CrossrefPubMedSuche in Google Scholar
  • 49 Nochaiwong S, Ruengorn C, Awiphan R. et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med 2022; 54: 80-97
    CrossrefPubMedSuche in Google Scholar
  • 50 Shao IY, Claxton JNS, Lutsey PL. et al. Association of Type of Antidepressant Initiation with Bleeding Risk in Atrial Fibrillation Patients Taking Oral Anticoagulants. Drugs – Real World Outcomes 2021; 8: 383-391
    CrossrefPubMedSuche in Google Scholar
  • 51 Alam SM, Qasswal M, Ahsan MJ. et al. Selective serotonin reuptake inhibitors increase risk of upper gastrointestinal bleeding when used with NSAIDs: a systemic review and meta-analysis. Sci Rep 2022; 12: 14452
    CrossrefPubMedSuche in Google Scholar
  • 52 de Abajo FJ, García-Rodríguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65: 795-803
    CrossrefPubMedSuche in Google Scholar
  • 53 Hou PC, Lin FJ, Lin SY. et al. Risk of Intracranial Hemorrhage With Concomitant Use of Antidepressants and Nonsteroidal Antiinflammatory Drugs: A Nested Case-Control Study. Ann Pharmacother 2021; 55: 941-948
    CrossrefPubMedSuche in Google Scholar
  • 54 Shin JY, Park MJ, Lee SH. et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal antiinflammatory drugs: nationwide propensity score matched study. BMJ 2015; 351: h3517
    CrossrefPubMedSuche in Google Scholar
  • 55 Nelva A, Guy C, Tardy-Poncet B. et al. Hemorrhagic syndromes related to selective serotonin reuptake inhibitor (SSRI) antidepressants. Seven case reports and review of the literature. Rev Med Interne 2000; 21: 152-160
    CrossrefPubMedSuche in Google Scholar
  • 56 Akca B, Siller-Matula J. Plättchenfunktionstestung: Erwartung und Realität. Journal für Kardiologie-Austrian. Journal of Cardiology 2013; 20: 160-167
    Suche in Google Scholar
  • 57 Calatzis A. Blutungszeit, Thrombelastographie und PFA-100. In: Hämostaseologie. Springer; 2010: 839-843
    CrossrefSuche in Google Scholar